Yahoo · Sep 17, 2026
Best Momentum Stocks to Buy for September 17th
MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
AS
NASDAQ · ASMB
Assembly Biosciences, Inc.
Healthcare · Biotechnology
$22.74
Down-$0.56 (-2.46%)
Updated Oct 6, 2026, 11:27 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 256.95M
- P/E ratio
- -5.93
- Dividend yield
- 0.00%
- 52-week range
- $21.80 – $37.01
- Volume
- 241.75K
- Avg. volume
- 121.21K
Price performance · ASMB
ASMB price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ASMB closed at $22.74 after 20 trading sessions, down 35.54% for the selected period.
- Last close
- $22.74
- Period change
- -35.54%
- Period low
- $22.54
- Period high
- $35.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $22.68 | $22.95 | $22.27 | $22.74 | 241.75K |
| Oct 2, 2026 | $23.30 | $23.4799 | $22.01 | $22.54 | 368.31K |
| Oct 1, 2026 | $23.18 | $23.66 | $22.75 | $22.98 | 350.8K |
| Sep 30, 2026 | $23.65 | $23.865 | $23.225 | $23.49 | 221.15K |
| Sep 29, 2026 | $23.70 | $23.79 | $23.05 | $23.48 | 229.74K |
| Sep 28, 2026 | $23.35 | $23.86 | $23.05 | $23.61 | 117.45K |
| Sep 25, 2026 | $23.70 | $24.2499 | $23.43 | $23.67 | 143.52K |
| Sep 24, 2026 | $23.73 | $24.02 | $23.15 | $23.66 | 179.02K |
| Sep 23, 2026 | $25.42 | $25.63 | $23.89 | $23.97 | 275.25K |
| Sep 22, 2026 | $25.69 | $25.89 | $25.12 | $25.45 | 1.07M |
| Sep 21, 2026 | $25.40 | $25.73 | $24.85 | $25.44 | 211.87K |
| Sep 18, 2026 | $25.41 | $25.78 | $24.83 | $24.97 | 1.41M |
| Sep 17, 2026 | $26.02 | $26.2958 | $25.10 | $25.34 | 364.77K |
| Sep 16, 2026 | $26.11 | $26.6926 | $25.13 | $25.48 | 348.79K |
| Sep 15, 2026 | $29.00 | $29.655 | $25.31 | $26.11 | 588.85K |
| Sep 14, 2026 | $30.31 | $30.48 | $28.79 | $28.96 | 290.47K |
| Sep 11, 2026 | $30.83 | $31.72 | $29.68 | $29.80 | 258.95K |
| Sep 10, 2026 | $32.56 | $32.69 | $30.34 | $30.46 | 348.62K |
| Sep 9, 2026 | $35.64 | $35.925 | $32.73 | $32.87 | 724.82K |
| Sep 8, 2026 | $36.16 | $36.68 | $35.145 | $35.28 | 227.77K |
Latest ASMB news
The latest Smart Investors Daily articles mentioning ASMB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ASMB research
Overview
Company profile and research snapshot.
Company profile
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $39.00
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | Mizuho | Outperform | — |
| Sep 1, 2026 | UBS | Buy | — |
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 15, 2026 | Mizuho | Outperform | — |
| May 28, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 17, 2026
New Strong Buy Stocks for September 17th
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
Yahoo · Sep 10, 2026
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be
Yahoo · Sep 8, 2026
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
